70 a) Traitement d'induction, p.70 ,
74 a) Traitement d'induction 74 b), p.75 ,
Variables ayant un impact significatif sur la survie 83 a) La qualité de la réponse après la première intensification-autogreffe 83 b) Le nombre de ligne de traitement avant intensification-autogreffe en rechute 86 d) Le temps jusqu'à progression après la première intensification-autogreffe, 84 c) L'exposition ou non aux nouvelles molécules e) La qualité de la réponse après autogreffe en rechute, p.91 ,
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation, Blood, vol.117, issue.23, pp.6063-73, 20119. ,
Hematopoietic stem cell transplantation for multiple myeloma beyond 2010, Blood, vol.115, issue.18, pp.3655-63, 2010. ,
DOI : 10.1182/blood-2009-08-238196
Improved survival in multiple myeloma and the impact of novel therapies, Blood, vol.111, issue.5, pp.2516-2536, 2008. ,
DOI : 10.1182/blood-2007-10-116129
Remarks on the Pathology of Mollities Ossium. With Cases, Journal of the Royal Society of Medicine, vol.27, issue.1, pp.435-498, 1844. ,
DOI : 10.1177/095952874402700129
Multiple myeloma. Blood, mars, vol.15111, issue.6, pp.2962-72, 2008. ,
URL : https://hal.archives-ouvertes.fr/hal-00557757
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study, Blood, vol.113, issue.22, pp.5412-5419, 2009. ,
DOI : 10.1182/blood-2008-12-194241
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance, New England Journal of Medicine, vol.346, issue.8, pp.564-573, 2002. ,
DOI : 10.1056/NEJMoa01133202
Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma, New England Journal of Medicine, vol.360, issue.25, pp.2645-54, 2009. ,
DOI : 10.1056/NEJMct0805626
Treatment of Multiple Myeloma: A Comprehensive Review, Clinical Lymphoma and Myeloma, vol.9, issue.4, pp.278-88, 2009. ,
DOI : 10.3816/CLM.2009.n.056
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial, Journal of Clinical Oncology, vol.27, issue.22, pp.3664-70, 2009. ,
DOI : 10.1200/JCO.2008.21.0948
Treatment of multiple myeloma]. Bull Cancer Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group, Br. J. Haematol, vol.93121, issue.15, pp.101-107, 2003. ,
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma, Leukemia, vol.22, issue.1, pp.3-9, 2009. ,
DOI : 10.1038/leu.2008.291
A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival, Cancer, vol.126, issue.3, pp.842-54, 1975. ,
DOI : 10.3181/00379727-125-32327
microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging., British Journal of Haematology, vol.26, issue.3, pp.439-486, 1983. ,
DOI : 10.1080/22953337.1980.11718773
International Staging System for Multiple Myeloma, Journal of Clinical Oncology, vol.23, issue.15, pp.3412-3432, 2005. ,
DOI : 10.1200/JCO.2005.04.242
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome, Blood, vol.109, issue.8, pp.3489-95, 2007. ,
DOI : 10.1182/blood-2006-08-040410
Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization, Cancer Res, vol.55, issue.17, pp.3854-3863, 1995. ,
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review, Leukemia, vol.91, issue.12, pp.2210-2231, 2009. ,
DOI : 10.1016/j.beha.2007.08.004
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy, Leukemia, vol.105, issue.3, pp.529-563, 2007. ,
DOI : 10.7326/0003-4819-115-12-931
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma, Leukemia, vol.91, issue.Suppl 1, pp.2034-2074, 2006. ,
DOI : 10.1016/j.ccr.2006.03.019
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2, Blood, vol.117, issue.18, pp.4696-700, 2011. ,
DOI : 10.1182/blood-2010-10-300970
Treatment of multiple myeloma. Blood, pp.20-32, 2004. ,
URL : https://hal.archives-ouvertes.fr/inserm-00368414
Bone marrow angiogenesis and progression in multiple myeloma, British Journal of Haematology, vol.324, issue.3, pp.503-511, 1994. ,
DOI : 10.1002/1097-0142(19930715)72:2<455::AID-CNCR2820720222>3.0.CO;2-8
Prise en charge du mélome multiple : traitement standard et nouveautés thérapeutiques, J Pharm Clin, vol.26, issue.1, pp.33-42, 2007. ,
Immunomodulatory Analogs of Thalidomide: An Emerging New Therapy in Myeloma, Journal of Clinical Oncology, vol.22, issue.16, pp.3212-3216, 2004. ,
DOI : 10.1200/JCO.2004.05.984
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma, New England Journal of Medicine, vol.341, issue.21, pp.1565-71, 1999. ,
DOI : 10.1056/NEJM199911183412102
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma, Blood, vol.100, issue.9, pp.3063-3070, 2002. ,
DOI : 10.1182/blood-2002-03-0996
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma, Leukemia, vol.305, issue.2, pp.414-437, 2008. ,
DOI : 10.1056/NEJMoa025313
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function, Cancer, vol.10, issue.16, pp.3807-3821, 2010. ,
DOI : 10.1002/cncr.25139
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies, Clin. Cancer Res, vol.8, issue.8, pp.2505-2516, 2002. ,
Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib, Journal of Clinical Oncology, vol.24, issue.19, pp.3113-3133, 2006. ,
DOI : 10.1200/JCO.2005.04.7779
Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations, Haematologica, vol.95, issue.2, pp.311-320, 2010. ,
DOI : 10.3324/haematol.2009.012674
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study, Blood, vol.109, issue.6, pp.2604-2610, 2007. ,
DOI : 10.1182/blood-2006-09-046409
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma, New England Journal of Medicine, vol.335, issue.2, pp.91-98, 1996. ,
DOI : 10.1056/NEJM199607113350204
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma, New England Journal of Medicine, vol.348, issue.19, pp.1875-83, 2003. ,
DOI : 10.1056/NEJMoa022340
High-dose Therapy with Single Autologous Transplantation versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials, Biology of Blood and Marrow Transplantation, vol.13, issue.2, pp.183-96, 2007. ,
DOI : 10.1016/j.bbmt.2006.09.010
Current Trends in Autologous Stem-Cell Transplantation for Myeloma in the Era of Novel Therapies, Journal of Clinical Oncology, vol.29, issue.14, pp.1898-906, 2011. ,
DOI : 10.1200/JCO.2010.32.5878
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma, New England Journal of Medicine, vol.349, issue.26, pp.2495-502, 2003. ,
DOI : 10.1056/NEJMoa032290
Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study, Journal of Clinical Oncology, vol.25, issue.17, pp.2434-2475, 2007. ,
DOI : 10.1200/JCO.2006.10.2509
Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM), Blood, vol.115, issue.1, pp.32-39, 2010. ,
DOI : 10.1182/blood-2009-06-229658
Optimizing peripheral blood progenitor cell autologous transplantation in multiple myeloma, Haematologica, vol.84, issue.6, pp.548-53, 1999. ,
An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy, Blood. nov, vol.1586, issue.10, pp.3961-3970, 1995. ,
Factors that influence collection and engraftment of autologous peripheral-blood stem cells., Journal of Clinical Oncology, vol.13, issue.10, pp.2547-55, 1995. ,
DOI : 10.1200/JCO.1995.13.10.2547
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100), Leukemia, vol.21, issue.10, pp.1904-1916, 2009. ,
DOI : 10.1038/sj.leu.2404284
The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone, Blood, vol.106, issue.5, pp.1867-74, 2005. ,
DOI : 10.1182/blood-2005-02-0468
Ten years of improvement in the management of multiple myeloma ,
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma, Blood, vol.106, issue.1, pp.35-44, 2005. ,
DOI : 10.1182/blood-2005-02-0522
Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial, Journal of Clinical Oncology, vol.28, issue.30, pp.4621-4630, 2010. ,
DOI : 10.1200/JCO.2009.27.9158
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma, Leukemia, vol.16, issue.9, pp.2035-2077, 2007. ,
DOI : 10.1007/s002770100351
Stem Cell Mobilization with Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Multiple Myeloma, Biology of Blood and Marrow Transplantation, vol.14, issue.7, pp.795-803, 2008. ,
DOI : 10.1016/j.bbmt.2008.04.008
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study, The Lancet, vol.376, issue.9758, pp.2075-85, 2010. ,
DOI : 10.1016/S0140-6736(10)61424-9
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma, Blood, vol.118, issue.22, pp.5752-5758, 2011. ,
DOI : 10.1182/blood-2011-05-355081
Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients: Primary Results of the IFM 20, -Frontline Therapy with Bortezomib-Miguel JF. How I treat multiple myeloma in younger patients, p.624, 2010. ,
Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group, Journal of Clinical Oncology, vol.24, issue.3, pp.431-437, 2006. ,
DOI : 10.1200/JCO.2005.03.0221
Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up, British Journal of Haematology, vol.9, issue.2, pp.512-518, 2008. ,
DOI : 10.1056/NEJMoa043445
Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide- Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial, ASH Annual Meeting Abstracts. Leukemia, vol.11223, issue.117, pp.1337-1378, 2008. ,
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma, Blood, vol.116, issue.5, pp.679-86, 2010. ,
DOI : 10.1182/blood-2010-02-268862
Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials, Journal of Clinical Oncology, vol.27, issue.34 ,
DOI : 10.1200/JCO.2008.21.1060
URL : https://hal.archives-ouvertes.fr/hal-00821143
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation, Blood, vol.118, issue.3, pp.529-563, 2011. ,
DOI : 10.1182/blood-2011-01-332320
Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents, Journal of Clinical Oncology, vol.28, issue.15, pp.2612-2636, 2010. ,
DOI : 10.1200/JCO.2009.25.4250
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1, Blood, vol.117, issue.18, pp.4691-4696, 2011. ,
DOI : 10.1182/blood-2010-10-299487
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma, Journal of Clinical Oncology, vol.28, issue.12, pp.2077-84, 2010. ,
DOI : 10.1200/JCO.2009.23.7172
Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial in BLOOD, pp.221-221, 2009. ,
Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer, pp.2171-80, 2006. ,
Results of a Multicenter Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma after Autologous Stem Cell Transplant, Clinical Cancer Research, vol.10, issue.24, pp.8170-8176, 2004. ,
DOI : 10.1158/1078-0432.CCR-04-1106
Posttransplantation Maintenance Therapy and Optimal Frontline Therapy in Myeloma, Hematology, vol.2011, issue.1, pp.197-204, 2011. ,
DOI : 10.1182/asheducation-2011.1.197
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma, Blood, vol.108, issue.10, pp.3289-94, 2006. ,
DOI : 10.1182/blood-2006-05-022962
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities, Blood, vol.112, issue.8, pp.3115-3136, 2008. ,
DOI : 10.1182/blood-2008-03-145235
Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure, Journal of Clinical Oncology, vol.27, issue.11, pp.1788-93, 2009. ,
DOI : 10.1200/JCO.2008.18.8573
Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences, Journal of Clinical Oncology, vol.28, issue.7, pp.1209-1223, 2010. ,
DOI : 10.1200/JCO.2009.25.6081
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma, New England Journal of Medicine, vol.366, issue.19, pp.1782-91, 2012. ,
DOI : 10.1056/NEJMoa1114138
URL : https://hal.archives-ouvertes.fr/hal-00852275
Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM), IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012 mars 29, pp.40-653003, 2009. ,
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3, British Journal of Haematology, vol.109, issue.2 ,
DOI : 10.1056/NEJMoa022340
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood, pp.176-851220, 2007. ,
Recent major improvement in long-term survival of younger patients with multiple myeloma, Blood, vol.111, issue.5, pp.2521-2527, 2008. ,
DOI : 10.1182/blood-2007-08-104984
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma, Haematologica, vol.95, issue.10, pp.1738-1782, 2010. ,
DOI : 10.3324/haematol.2009.015917
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma, British Journal of Haematology, vol.108, issue.1, pp.46-53, 2008. ,
DOI : 10.1111/j.1365-2141.2008.07303.x
Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and « retreatment » approaches in the era of novel agents. Leukemia. 2012 janv, pp.73-85 ,
Thalidomide for treatment of multiple myeloma: 10 years later, Blood, vol.111, issue.8, pp.3968-77, 2008. ,
DOI : 10.1182/blood-2007-10-117457
Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives, Journal of Clinical Oncology, vol.21, issue.23, pp.4444-54, 2003. ,
DOI : 10.1200/JCO.2003.07.200
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America, New England Journal of Medicine, vol.357, issue.21, pp.2133-2175, 2007. ,
DOI : 10.1056/NEJMoa070596
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma, Leukemia, vol.23, issue.11, pp.2147-52, 2009. ,
DOI : 10.1056/NEJMoa0801479
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma, New England Journal of Medicine, vol.348, issue.26, pp.2609-2626, 2003. ,
DOI : 10.1056/NEJMoa030288
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma, British Journal of Haematology, vol.16, issue.2, pp.165-72, 2004. ,
DOI : 10.1111/j.1365-2141.2004.05188.x
Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression, Journal of Clinical Oncology, vol.25, issue.25 ,
DOI : 10.1200/JCO.2006.10.5460
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study, Leukemia, vol.16, issue.1, pp.149-57, 2012. ,
DOI : 10.1182/blood-2006-08-040410
Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation, British Journal of Haematology, vol.24, issue.18, pp.41-51, 2008. ,
DOI : 10.1097/00001721-200204000-00003
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma, Journal of Clinical Oncology, vol.22, issue.16 ,
DOI : 10.1200/JCO.2004.10.052
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma, Journal of Clinical Oncology, vol.27, issue.30, pp.5008-5022, 2009. ,
DOI : 10.1200/JCO.2009.23.6802
Carfilzomib: a novel second-generation proteasome inhibitor, Future Oncology, vol.27, issue.5, pp.607-619, 2011. ,
DOI : 10.1158/1078-0432.CCR-09-0822
Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma, Journal of Clinical Oncology, vol.30, issue.16 ,
DOI : 10.1200/JCO.2011.37.2649
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial, British Journal of Haematology, vol.15, issue.Suppl. ,
DOI : 10.1111/j.1365-2141.2008.07076.x
Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma, Leukemia & Lymphoma, vol.90, issue.12, pp.2345-51, 2007. ,
DOI : 10.1046/j.1365-2141.1998.00930.x
Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres, British Journal of Haematology, vol.36, issue.1, pp.209-225, 2001. ,
DOI : 10.1038/sj.bmt.1701546
Reducedintensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood, avr, vol.15109, issue.8, pp.3588-94, 2007. ,
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma, Blood, vol.107, issue.9, pp.3474-80, 2006. ,
DOI : 10.1182/blood-2005-09-3869
Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up, Journal of Clinical Oncology, vol.29, issue.22, pp.3016-3038, 2011. ,
DOI : 10.1200/JCO.2010.32.7312
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial, The Lancet Oncology, vol.12, issue.13, pp.1195-203, 2011. ,
DOI : 10.1016/S1470-2045(11)70243-1
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT, Blood, vol.105, issue.11, pp.4532-4541, 2005. ,
DOI : 10.1182/blood-2004-06-2387
International uniform response criteria for multiple myeloma, Leukemia, vol.27, issue.9, pp.1467-73, 2006. ,
DOI : 10.1038/sj.bmt.1703035
Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival, Biology of Blood and Marrow Transplantation, vol.18, issue.5, pp.773-782, 2012. ,
DOI : 10.1016/j.bbmt.2011.10.044
Durable remission with salvage second autotransplants in patients with multiple myeloma, Cancer, vol.26, issue.14 ,
DOI : 10.1200/JCO.2007.14.2372
Melphalan 100???mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation, European Journal of Haematology, vol.16, issue.2, pp.117-139, 2011. ,
DOI : 10.1016/j.bbmt.2010.04.002
Factors Influencing the Outcome of a Second Autologous Stem Cell Transplant (ASCT) in Relapsed Multiple Myeloma: A Study from the British Society of??Blood and Marrow Transplantation Registry, Biology of Blood and Marrow Transplantation, vol.17, issue.11, pp.1638-1683, 2011. ,
DOI : 10.1016/j.bbmt.2011.04.005
Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation, Leukemia & Lymphoma, vol.114, issue.1, pp.1455-62, 2011. ,
DOI : 10.1038/bmt.2008.343
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma, Bone Marrow Transplantation, vol.16, issue.5, pp.417-439, 2009. ,
DOI : 10.1182/blood-2007-07-101212
Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival, Biology of Blood and Marrow Transplantation, vol.18, issue.5, pp.773-782, 2012. ,
DOI : 10.1016/j.bbmt.2011.10.044
Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma, Leukemia & Lymphoma, vol.16, issue.9, pp.1442-1449, 2009. ,
DOI : 10.1038/sj.leu.2405062
Impact of early relapse after auto-SCT for multiple myeloma, Bone Marrow Transplantation, vol.25, issue.6, pp.413-433, 2008. ,
DOI : 10.1056/NEJMoa032290
Transplantation as salvage therapy for high-risk patients with myeloma in relapse, Bone Marrow Transplantation, vol.19, issue.12, pp.873-881, 2002. ,
DOI : 10.1200/JCO.2001.19.16.3675
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure, Blood, vol.112, issue.12, pp.4445-51, 2008. ,
DOI : 10.1182/blood-2008-02-141614
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy, Cancer, vol.100, issue.7, pp.1529-1566, 2008. ,
DOI : 10.1002/cncr.23326
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study, Leukemia, vol.16, issue.4, pp.842-851, 2008. ,
DOI : 10.1046/j.1365-2141.1998.00930.x
Pathogenesis and treatment of renal failure in multiple myeloma, Leukemia, vol.39, issue.8, pp.1485-93, 2008. ,
DOI : 10.1016/S0272-6386(12)81021-3
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma, New England Journal of Medicine, vol.366, issue.19, pp.1782-91, 2012. ,
DOI : 10.1056/NEJMoa1114138
URL : https://hal.archives-ouvertes.fr/hal-00852275
VTD combination therapy with bortezomib|[ndash]|thalidomide|[ndash]|dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia, pp.1419-1446, 2008. ,
bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study, Journal of clinical oncology: official journal of the American Society of Clinical Oncology. Post-Meetong Edition, 2009. ,